Investor Presentaiton

4 Nyxoah's Blueprint for Success >$10bn US HGNS Market Opportunity with <5% Penetration and Established Reimbursement GenioⓇ - A Breakthrough and Disruptive Hypoglossal Nerve Stimulation Solution Proof-of-Concept European Commercialization De-risked Pivotal Study with a US Launch in 2024 and CCC Label Expansion in 2026 Nyxoah

View entire presentation